Given that Alzheimer's disease is multifactorial and heterogenous, drug development progress is more likely to occur if multiple pathways are considered. Two recent Nature publications have potentially identified medin and PLD3 as new targets for Alzheimer’s disease treatment, which we summarize in this mini-review.
Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
This article, originally published on Scientist.com, reviews the current standard of care for glioblastoma multiforme (GBM), challenges in developing accurate preclinical GBM models and effective therapies, and the future of GBM drug discovery.
The combination of anti-cancer drugs, or combination therapy, has been hailed as a “cornerstone of cancer therapy” since it targets key pathways synergistically, thereby enhancing efficacy compared to monotherapies. This blog takes a look at a recent publication in Nature, which reported the effects of 2025 pairwise drug combinations in breast, colon, and pancreatic cell lines.
Bin Xie discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.
Anuj Kalsy and Robert Snyder showcase Precision for Medicine's variant-rich biobank, including discussion on biospecimen types, applications, screening methods, and support for companion diagnostic development.
Experts provide a showcase of Precision for Medicine's variant-rich biobank. including discussion on biospecimen types, applications, screening methods, and support for companion diagnostic development.
Dr. Bin Xie discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.
Richard Kondo, McLean Collins, and Cathie G. Miller highlighted Episode 3 of the Cutting Edge Conversations series focused on innovations in the area of sourcing human biosamples for research. The event focused on sourcing human samples for research, including the value and necessity of working with human tissue during drug discovery, as well as some of the distinct challenges researchers face.
Dr. Danny Chou discusses the opportunities and challenges in orthogonal particle analysis, and how flow imaging microscopy and light obscuration can be used for formulation development and quality control.